Murtuza Vasanwala

Founder & Managing Director

Active Pharmaceutical Ingredients (APIs) sit at the core of every pharmaceutical product, making API manufacturers critical to the global healthcare ecosystem. Over the past few years, however, the role of API companies has evolved considerably. Pharmaceutical firms today are no longer evaluating suppliers solely on pricing or production scale. Increasingly, they are looking for manufacturing partners with strong regulatory sys­tems, technical depth, and the ability to ensure long-term supply reliability.

This shift has created a significant opportunity for Indian API manufacturers. The global ‘China Plus One’ strategy, driven by companies seeking to diversify supply chains, has accelerated international interest in India’s pharmaceutical manufacturing capabilities. Combined with India’s growing regulatory maturity and technical expertise, the country is steadily strengthening its position as a dependable global API sourcing destination.

Among the companies aligning themselves with this changing landscape is Medikament Pharma. Since its establishment in 2016, the company has focused on building a manufacturing and research environment centered on compliance, scientific capability, and process reliability rather than competing purely on volume.

Building the Company Around Compliance

From the beginning, Medikament Pharma approached compliance as a core operational philosophy rather than a later-stage requirement. The company invested early in GMP-compliant infrastructure, quality systems, and scientific talent, with the intention of creating a facility capable of meeting the expectations of regulated international markets.

Over time, that approach has expanded beyond documentation and audit preparedness. Today, the company’s operations incorporate electronic batch manufacturing records, real-time environmental monitoring systems, and data integrity practices aligned with international standards.

What distinguishes the company’s approach is its emphasis on transparency and technical engagement with customers. Rather than functioning only as a manufacturing vendor, Medikament Pharma increasingly works as a development and process partner for pharmaceutical companies navigating complex regulatory and commercial requirements.

“We started as a manufacturer. We have grown into a scientific partner in the development and reliable supply of critical pharmaceutical raw materials, and that distinction shapes every strategic choice we make”, speaks Murtuza Vasanwala, Founder & Managing Director, Medikament Pharma.

Focused Specialization Instead of Portfolio Expansion

While many API manufacturers pursue extensive product catalogs, Medikament Pharma has taken a more selective route. The company has concentrated its efforts on therapeutic areas such as cardiovascular, anti-infective, antidiabetic, and oncology APIs.

This focused strategy allows the organization to develop deeper expertise in areas such as impurity profiling, polymorph control, and complex synthesis processes factors that are increasingly important in regulated pharmaceutical markets.

The company also works on Novel Chemical Entities (NCEs) and R&D-scale contract synthesis projects, enabling collaboration with pharmaceutical companies during early-stage development.

Another important part of its product strategy involves monitoring the IP landscape and upcoming patent expiries. By identifying molecules, where technical complexity creates higher entry barriers, the company aims to compete through process capability and regulatory strength rather than entering purely price-driven markets.

Bridging the Gap Between Development and Scale-Up

One of the recurring challenges in pharmaceutical manufacturing is ensuring that processes developed at laboratory scale remain stable and commercially viable during large-scale production.

Medikament Pharma addresses this by integrating process development, impurity assessment, and scalability evaluations early in the development cycle. This reduces the likelihood of delays or costly modifications during commercial manufacturing and regulatory filing stages. The company also supports lifecycle management activities including process optimization, technology transfer, and regulatory documentation support.

This technical involvement has, in some cases, played a direct role in resolving customer challenges. In one engagement, a customer encountered an unexpected impurity issue that threatened to delay a regulatory submission. Medikament Pharma’s R&D team worked to identify the source of the degradant, redesign the synthesis approach, and implement tighter in-process controls, allowing the customer to proceed within the original submission timeline.

Creating a Culture of Scientific Ownership

Like much of the pharmaceutical industry, the API sector continues to face strong competition for experienced scientific and regulatory talent. Medikament Pharma’s response has been to build what it describes as a culture of ‘scientific ownership’, where technical teams are encouraged to contribute to route scouting, process optimization, and analytical problem-solving instead of working within narrowly defined operational roles. The company believes this environment of involvement and accountability plays an important role in retaining skilled professionals.

Looking Ahead

Going forward, Medikament Pharma is investing in expanded manufacturing infrastructure, digital manufacturing systems, and sustainability-focused process development. The company is also preparing for a planned entry into biosimilar APIs and oral insulin manufacturing by 2028, marking a move into more technically demanding and higher-value segments of the pharmaceutical industry.

Alongside expansion, sustainability remains an area of focus, particularly through solvent recovery systems, waste reduction initiatives, and greener synthesis approaches. As global pharmaceutical supply chains continue to evolve, companies that combine scientific capability with operational reliability are likely to play a larger role in the industry’s future. Medikament Pharma’s trajectory reflects that broader shift taking place across India’s API sector, from scale-driven manufacturing toward more research-oriented and compliance-focused partnerships.